ACR Convergence 2020

The all-virtual ACR Convergence 2020 experience includes the highest-quality educational content along with innovative session formats and multiple opportunities to network with colleagues. We invite you to explore The Rheumatologist’s complete coverage of the meeting. Plus, explore our resource centers focused on rheumatoid arthritis, systemic lupus erythematosus and gout, along with our collection of research reviews, case reports and clinical articles on advances in the diagnosis and management of these conditions.

FDA Provides 2020 Rheumatology Drug Update

Three FDA representatives discuss new drug indications, safety precautions and label changes, & an emergency program to rapidly evaluate existing immunomodulating therapies for use in COVID-19 patients.... [Read More]

A Closer Look at Antibodies in RA: How Anti-Citrullinated Protein Antibodies, Anti-Modified Protein Autoantibodies & Rheumatoid Factor Activity Overlap

Recent evidence on how anti-citrullinated protein antibodies, anti-modified protein autoantibodies and rheumatoid factor activity overlap in RA demonstrate new ideas for diagnostics and pathophysiology.... [Read More]

Therapeutic Exercise for Bone Health

ACR CONVERGENCE 2020—Attention to bone health in people at risk of developing, or who already have, osteoporosis is essential to reduce their increased risk for fragility fractures. Major risk factors for osteoporosis include being female, white, of small frame and having a family history of osteoporosis, as well as having secondary causes of osteoporosis, such… [Read More]

Back to Basics: The 2020 Basic Science Year in Review

The 2020 Basic Science Year in Review covered autoantibody origin and persistence, insights into the major histocompatibility complex and factors in rheumatoid arthritis progression and relapse.... [Read More]

Telerheumatology: What’s Next?

In an ACR Convergence session, two rheumatologists discussed how COVID-19 changed the use of telemedicine, how payers reacted and which changes are likely permanent and which are likely to be temporary.... [Read More]

Evaluation & Treatment of Systemic Sclerosis-ILD in the New Decade

ACR Convergence panelists discussed how to monitor SSc-ILD patients for ILD severity & the brightening prospects for therapy.... [Read More]

The 2020 ACR Review Course: Key Issues Rheumatologists Face

The ACR Review Course featured eight talks providing a practical review of issues encountered by rheumatologists.... [Read More]

New Clinical Insights into the Pathogenesis, Diagnosis & Treatment of Calcium Pyrophosphate Arthritis

New diagnostic approaches combined with new evidence about pathogenesis are providing opportunities to help rheumatologists manage calcium pyrophosphate deposition disease.... [Read More]

The 2020 ARP Merit Awards & ACR Distinguished Fellows

During ACR Convergence 2020 in early November, the ACR and ARP honored a group of distinguished individuals who have made significant contributions to rheumatology research, education and patient care. This month, The Rheumatologist speaks with the winners of the ARP Merit Awards and the ACR’s Distinguished Fellows. In addition, we bring you the first ever… [Read More]

Long-Term Safety of Baricitinib for RA

Baricitinib appears to be a safe long-term treatment for RA patients, according to a recent analysis of patients with drug exposure up to eight years.... [Read More]